Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Journal for Immunotherapy of Cancer|October 9, 2025
Expansion of a circulating Ki67-positive effector T-cell population following combined PD-1 and CTLA-4 blockade for melanoma is predictive of treatment responseJack M Edwards, Sashendra Senthi, Robin Smith, et al.
Clinical and Experimental Hypertension (New York, N.Y. : 1993)|November 13, 2007
Antioxidant vitamins and adrenocorticotrophic hormone-induced hypertension in ratsChristopher G Schyvens, Miles C Andrews, Rachel Tam, et al.
Frontiers in Oncology|April 6, 2026
Case Report: Successful treatment of steroid-refractory severe immunotherapy-induced pneumonitis with equine antithymocyte globulinThi Thao Vi Luong, Lindon Lin, John Coutsouvelis, et al.
Frontiers in Immunology|March 20, 2018
Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic MelanomaJessica Da Gama Duarte, Sagun Parakh, Miles C Andrews, et al.
Cardio-Oncology (London, England)|December 2, 2022
Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort studyCharlie Wang, Sophia Zoungas, Mabel Yan, et al.
American Journal of Hypertension|August 2, 2005
Apocynin but not allopurinol prevents and reverses adrenocorticotropic hormone-induced hypertension in the ratYi Zhang, Matthew M K Chan, Miles C Andrews, et al.
JHLT Open|March 27, 2025
Malignancy risk and mortality after lung transplantation: A single-institution experience over 31 yearsHui-Ling Yeoh, Helen Shingles, Eldho Paul, et al.
Clinical & Translational Immunology|September 11, 2023
Design, optimisation and standardisation of a high-dimensional spectral flow cytometry workflow assessing T-cell immunophenotype in patients with melanomaJack M Edwards, Miles C Andrews, Hayley Burridge, et al.
JCO Precision Oncology|June 7, 2024
Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic MelanomaMiles C Andrews, Gerald Li, Ryon P Graf, et al.
Cell|August 15, 2017
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeSpencer C Wei, Jacob H Levine, Alexandria P Cogdill, et al.
Pageof 6